| Oct 18 |
State Street Corp's Strategic Acquisition in Vir Biotechnology Inc
|
| Oct 17 |
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
|
| Oct 15 |
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
|
| Oct 5 |
Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company
|
| Oct 3 |
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
|
| Sep 10 |
Vir Biotechnology names Jason O’Byrne as CFO
|
| Sep 10 |
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
|
| Sep 9 |
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
|
| Aug 22 |
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 6 |
Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?
|
